Skip to main content

Table 3 Costs (SEK) of health care and treatments (including cardiovascular costs) before and after starting the insulin treatment

From: Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice

 

Pre-index

Post-index

Increment

Net cost effect

 

Health care

Treatment

Health care

Treatment

Health care

Treatment

Treatment

Mean/Median

Mean/Median

Mean/Median

Mean/Median

Mean/Median

Mean/Median

Mean/Median

NPH

24,791/3,681

3,449/2,398

19,390/3,681

9,279/7,879

−5,401/0

5,831/4,659

430/4,659

IG

25,197/3,681

3,920/2,679

23,539/3,681

11,967/10,670

−1,658/0

8,047/6,569

6,389/6,569

ID

17,981/2,613

3,815/2,194

13,070/2,955

13,143/11,306

−4,912/0

9,328/7,808

4,416/7,808

PM

36,724/6,366

3,183/2,259

26,388/4,262

9,744/8,800

−10,336/-773

6,560/6,010

−3,776/5,237

p-values

<0.0001

<0.0012

<0.0001

<0.0001

0.0022

<0.0001

 
  1. NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is currently 12 US dollars (August 2015)